Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Berenberg European Conference USA 2015
12 slides from Coloplast A/s Class B's conference presentation, 2015
Slide 1: Value creation through profitable growth
Value creation through profitable growth Berenberg European Conference USA 2015 Lars Rasmussen, President & CEO Page 1
Slide 2: In recent years we have delivered great results
In recent years we have delivered great results Coloplast EBIT margin versus peer group (%) 40 35 33 Outperforming 30 Coloplast AS 25 Median 20 22 peers 15 10 Upper quartile 09/10 13/14 Total Shareholder Return* ~38% CAGR Attractive shareholder return 07/08 08/09 09/10 10/11 11/12 12/13 13/14 Colopl
Slide 3: Our strategy remains centred on value creation through profitable organic growth
Our strategy remains centred on value creation through profitable organic growth How we compete Where we compete Develop and market the world’s best products Untapped potential in Europe Increased momentum in Other Developed Markets Interact and build consumers relations – incl. breakthrough
Slide 4: We have launched significant innovative consumer oriented products in all areas...
We have launched significant innovative consumer oriented products in all areas... - Continence Care - - Ostomy Care - - Wound Care - - Urology Care - Page 4
Slide 5: We believe consumer relations will be key to our future success
We believe consumer relations will be key to our future success and we reach out to consumers via two programs Coloplast® Care Direct-to-Consumer CARE is a retention program Direct-to-Consumer is a marketing program Page 5
Slide 6: We currently invest to grow…
We currently invest to grow… Sales investments*... Rep count development 2012 to 2013 ...by type: Other 15% +10% Consumer programs Sales force 25% 60% ...by area: Europe 20% Other Developed Emerging Markets Markets 60% 2012 2013 20% * 12/13 to Q2 13/14. HQ investments allocated to geographies pro ra
Slide 7: ...and we have great potential for further sales investments
...and we have great potential for further sales investments - Key areas for further investments - European Markets Other Developed Emerging Markets Markets Ostomy Care Build markets and Consumer programs Capture fair share secure leadership Continence Care Wound & Skin Care Expand Wound Care Urolog
Slide 8: We have an ambitious long term guidance
We have an ambitious long term guidance Revenue growth EBIT margin A B - annual organic - - annual expansion - 7 – 10% 0.5 – 1.0% Page 8
Slide 9: We accelerate volume growth and manage price pressure...
A We accelerate volume growth and manage price pressure... Market (all-else-equal) Coloplast efforts Net effect on Coloplast Volume Mid single Share High single digit growth gains digit growth Price ~1% < ~1% price Price price pressure optimization pressure Mix Ongoing Relatively Up value unchanged
Slide 10: ...while driving economies of scale in our cost functions
B ...while driving economies of scale in our cost functions Cost item Development Outlook Outlook As reported Percentage of revenue Scalability potential Investments requirements COGS 38.7 31.3 0 High Medium 09/10 13/14 Distribution 29.5 28.3 0 Medium High 09/10 13/14 Admin 5.8 4.0 0 High Low 09/10
Slide 11: In sum, Coloplast offers an attractive investment case
In sum, Coloplast offers an attractive investment case with continued value creation through profitable growth Value creation Organic Scalable commercial business potential model Stable and attractive market fundamentals Page 11
Slide 12: Our mission, values and vision
Our mission Making life easier for people with intimate healthcare needs Our values Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us Our vision Setting the global standard for listening and responding = Coloplast p